Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 9, keine Gesamtzahl für „weeks“
Suchtreffer
Begriffe & Kennungen
Jyseleca · 4.8 · In placebo-controlled Phase 3 studies with background DMARDs (FINCH 1 and FINCH 2) through 12 weeks, serum pho
Eintrag öffnenJyseleca · 4.8 · In placebo-controlled studies with background DMARDs, the frequencies of infectious ADRs over 12 weeks for fil
Eintrag öffnenJyseleca · 4.8 · In placebo-controlled studies with background DMARDs, the frequency of serious infection over 12 weeks in the
Eintrag öffnenJyseleca · 4.8 · Nausea Nausea was generally transient and reported during the first 24 weeks of filgotinib treatment.
Eintrag öffnenKaletra · 4.5 · 88 monitoring should be conducted, particularly before and during 2 weeks after starting or stopping Kaletra,
Eintrag öffnenKalydeco · 4.8 · During the placebo-controlled phase 3 studies (up to 24 weeks) of tezacaftor/ivacaftor, the incidence of maxim
Eintrag öffnenKalydeco · 4.8 · During the placebo-controlled phase 3 studies (up to 24 weeks) of tezacaftor/ivacaftor, the incidence of maxim
Eintrag öffnenKalydeco · 4.8 · Safety of ivacaftor as monotherapy for 24 weeks was evaluated in 43 patients between 1 month to less than 24 m
Eintrag öffnenKalydeco · 4.8 · Safety of ivacaftor as monotherapy for 24 weeks was evaluated in 43 patients between 1 month to less than 24 m
Eintrag öffnenKesimpta · 4.8 · Ofatumumab was associated with a transient decrease of 4.3% in mean IgG levels after 48 weeks of treatment but
Eintrag öffnenKevzara · 4.8 · Lipids Lipid parameters (LDL, HDL, and triglycerides) were first assessed at 4 weeks following initiation of s
Eintrag öffnenKeytruda · 4.8 · Immunogenicity In clinical studies in patients treated with pembrolizumab 2 mg/kg bw every three weeks, 200 mg
Eintrag öffnenKineret · 4.8 · Injection site reactions ISRs typically appear within 2 weeks of therapy and disappear within 4-6 weeks. The d
Eintrag öffnenKiovig · 4.5 · Immunoglobulin administration may impair for a period of at least 6 weeks and up to 3 months the efficacy of l
Eintrag öffnenKymriah · 4.8 · 15 the patients experienced an infection of any type within 8 weeks.
Eintrag öffnenKymriah · 4.8 · Grade 3 and 4 adverse reactions were more often observed within the initial 8 weeks post infusion (70%) compar
Eintrag öffnenKymriah · 4.8 · Grade 3 and 4 adverse reactions were more often observed within the initial 8 weeks post infusion (78% of pati
Eintrag öffnenKymriah · 4.8 · Grade 3 and 4 adverse reactions were more often observed within the initial 8 weeks post infusion (82%) compar
Eintrag öffnenKymriah · 4.8 · Neurological adverse reactions The majority of neurotoxic events occurred within 8 weeks following infusion an
Eintrag öffnenLedaga · 4.8 · In a randomised-controlled trial (n=128 exposed to Ledaga for a median duration of 52 weeks), the most frequen
Eintrag öffnen